Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI).
Sharma A, Kaiser PK, Tadayoni R, Holz FG, Nicholson L, Vazquez-Alfageme C, Sivaprasad S, Wakabayashi T, Woo SJ, Sarraf D, Kumar N, Parachuri N, Regillo CD, Rezaei KA, Khanani AM, Bandello F, Shanamugam M, Verma L, Dogra MR, Ns M, Agarwal M, Loewenstein A, Kuppermann BD; International Retina Biosimilar Study Group (Inter BIOS Group). Sharma A, et al. Among authors: kumar n. Eye (Lond). 2024 Dec;38(17):3392-3395. doi: 10.1038/s41433-024-03284-x. Epub 2024 Aug 26. Eye (Lond). 2024. PMID: 39187656 No abstract available.
Biologics, biosilimars, and biobetters: different terms or different drugs?
Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Sharma A, et al. Among authors: kumar n. Eye (Lond). 2019 Jul;33(7):1032-1034. doi: 10.1038/s41433-019-0391-5. Epub 2019 Mar 7. Eye (Lond). 2019. PMID: 30846867 Free PMC article. Review. No abstract available.
Biotherapeutics and immunogenicity: ophthalmic perspective.
Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Sharma A, et al. Among authors: kumar n. Eye (Lond). 2019 Sep;33(9):1359-1361. doi: 10.1038/s41433-019-0434-y. Epub 2019 Apr 9. Eye (Lond). 2019. PMID: 30967643 Free PMC article. No abstract available.
Brolucizumab: is extended VEGF suppression on the horizon?
Sharma A, Kumar N, Kuppermann BD, Loewenstein A, Bandello F. Sharma A, et al. Among authors: kumar n. Eye (Lond). 2020 Mar;34(3):424-426. doi: 10.1038/s41433-019-0582-0. Epub 2019 Sep 16. Eye (Lond). 2020. PMID: 31527765 Free PMC article. No abstract available.
Abicipar pegol: the non-monoclonal antibody anti-VEGF.
Sharma A, Kumar N, Kuppermann BD, Bandello F. Sharma A, et al. Among authors: kumar n. Eye (Lond). 2020 May;34(5):797-801. doi: 10.1038/s41433-019-0607-8. Epub 2019 Sep 30. Eye (Lond). 2020. PMID: 31570812 Free PMC article. No abstract available.
Ophthalmic biosimilars and biologics-role of endotoxins.
Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Sharma A, et al. Among authors: kumar n. Eye (Lond). 2020 Apr;34(4):614-615. doi: 10.1038/s41433-019-0636-3. Epub 2019 Oct 16. Eye (Lond). 2020. PMID: 31619778 Free PMC article. No abstract available.
Faricimab: expanding horizon beyond VEGF.
Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Sharma A, et al. Among authors: kumar n. Eye (Lond). 2020 May;34(5):802-804. doi: 10.1038/s41433-019-0670-1. Epub 2019 Nov 6. Eye (Lond). 2020. PMID: 31695160 Free PMC article. No abstract available.
9,414 results